REGENXBIO, Inc. RGNX
NASDAQ · United States · Health Technology
$7.42-0.11 (-1.46%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
| Quarter | Report date | Actual EPS | Estimated EPS | EPS surprise | Actual revenue | Revenue surprise | Price reaction |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 2026-08-06 | 0.43 | 0.08 | +446.2% | $108.02M | +10.6% | +2.1%$10.50→$10.72 |
| Q1 2026 | 2026-05-14 | -1.72 | -1.41 | -22.0% | — | — | -43.0%$10.04→$5.72 |
| Q4 2025 | 2026-03-05 | -1.30 | -0.84 | -54.8% | — | — | -5.4%$9.14→$8.65 |
| Q3 2025 | 2025-11-06 | -1.20 | -1.38 | +13.0% | — | — | -3.4%$11.61→$11.21 |
| Q1 2025 | 2025-05-12 | 0.12 | 0.49 | -75.5% | — | — | — |
| Q4 2024 | 2025-03-13 | -1.01 | -1.08 | +6.5% | — | — | — |
| Q3 2024 | 2024-11-06 | -1.17 | -1.10 | -6.4% | — | — | — |
| Q1 2024 | 2024-05-08 | -1.34 | -1.26 | -6.3% | — | — | — |
The price reaction is the change from the last close before the announcement date to the first close after it - the report may land before the open, during the session or after the close, so this window covers all three. Not investment advice.